Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Amortization (2016 - 2020)

Historic Amortization for Summit Therapeutics (SMMT) over the last 5 years, with Q1 2020 value amounting to -$7.4 million.

  • Summit Therapeutics' Amortization fell 19272.52% to -$7.4 million in Q1 2020 from the same period last year, while for Mar 2020 it was -$55.7 million, marking a year-over-year increase of 3981.77%. This contributed to the annual value of $79.9 million for FY2019, which is N/A changed from last year.
  • Per Summit Therapeutics' latest filing, its Amortization stood at -$7.4 million for Q1 2020, which was down 19272.52% from -$46.9 million recorded in Q4 2019.
  • Summit Therapeutics' 5-year Amortization high stood at $59.8 million for Q1 2019, and its period low was -$91.6 million during Q1 2017.
  • Moreover, its 5-year median value for Amortization was $32.4 million (2019), whereas its average is $17.4 million.
  • Per our database at Business Quant, Summit Therapeutics' Amortization tumbled by 25835.61% in 2017 and then soared by 65962.47% in 2019.
  • Quarter analysis of 5 years shows Summit Therapeutics' Amortization stood at $47.3 million in 2016, then plummeted by 99.31% to $325393.4 in 2017, then soared by 12494.02% to $41.0 million in 2018, then plummeted by 214.55% to -$46.9 million in 2019, then soared by 84.14% to -$7.4 million in 2020.
  • Its Amortization stands at -$7.4 million for Q1 2020, versus -$46.9 million for Q4 2019 and $32.4 million for Q4 2019.